BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31676179)

  • 1. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
    Freixo C; Ferreira V; Martins J; Almeida R; Caldeira D; Rosa M; Costa J; Ferreira J
    J Vasc Surg; 2020 Jan; 71(1):318-327. PubMed ID: 31676179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.
    Sandbank S; Molho-Pessach V; Farkas A; Barzilai A; Greenberger S
    Acta Derm Venereol; 2019 Oct; 99(11):990-996. PubMed ID: 31304557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
    Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
    Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral sirolimus for high-flow vascular malformations in real clinical practice.
    Durán-Romero AJ; Hernández-Rodríguez JC; Ortiz-Álvarez J; Domínguez-Cruz JJ; Monserrat-García MT; Conejo-Mir Sánchez J; Bernabeu-Wittel J
    Clin Exp Dermatol; 2022 Jan; 47(1):57-62. PubMed ID: 34240451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
    Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
    Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus for the treatment of children with various complicated vascular anomalies.
    Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
    Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus in the Treatment of Vascular Anomalies.
    Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
    Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
    Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
    Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
    Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
    Geeurickx M; Labarque V
    J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sirolimus in the treatment of vascular malformations: A protocol for systematic review and meta-analysis.
    Dong J; Han D; Wang D; Lu H; Wang X
    Medicine (Baltimore); 2020 Oct; 99(40):e22596. PubMed ID: 33019479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
    Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
    Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
    Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review.
    Nadal M; Giraudeau B; Tavernier E; Jonville-Bera AP; Lorette G; Maruani A
    Acta Derm Venereol; 2016 May; 96(4):448-52. PubMed ID: 26607948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations.
    Triana P; Miguel M; Díaz M; Cabrera M; López Gutiérrez JC
    Lymphat Res Biol; 2019 Oct; 17(5):504-511. PubMed ID: 30985248
    [No Abstract]   [Full Text] [Related]  

  • 16. A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations.
    Blatt J; McLean TW; Castellino SM; Burkhart CN
    Pharmacol Ther; 2013 Sep; 139(3):327-33. PubMed ID: 23665062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
    Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
    JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
    Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
    Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants.
    Czechowicz JA; Long-Boyle JR; Rosbe KW; Mathes EF; Frieden IJ; Shimano KA
    Int J Pediatr Otorhinolaryngol; 2018 Feb; 105():48-51. PubMed ID: 29447818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective multicenter study of sirolimus for complicated vascular anomalies.
    Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
    J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.